Nanotechnology Now - Press Release: BioAlliance Pharma Publishes Its 2009 Financial Calendar

Home > Press > BioAlliance Pharma Publishes Its 2009 Financial Calendar

Abstract:
BioAlliance Pharma SA (Paris:BIO) has announced its financial calendar for 2009, which notably includes the publication dates for its revenue statements and half-year & annual accounts, as well as the date of its shareholders' Annual General Meeting:

BioAlliance Pharma Publishes Its 2009 Financial Calendar

Paris, France | Posted on January 15th, 2009

February 11, 2009

Publication of the revenue statement for Q4 2008 and of the annual revenue statement

March 6, 2009 Publication of the consolidated accounts for 2008

SFAF analyst meeting at the company's head office

April 11, 2009

Publication of the Company's annual report and French "Document de Référence" for 2008

April 29, 2009 Annual General Meeting at the company's head office

April 30, 2009 Publication of the revenue statement for Q1 2009

July 23, 2009 Publication of the revenue statement for Q2 2009

August 27, 2009

Publication of the consolidated half-year accounts as of June 30 2009. SFAF analyst meeting at the company's head office

October 22, 2009 Publication of the revenue statement for Q3 2009

Along with other information on BioAlliance Pharma S.A., a regularly updated "Investors" section is available on the company's website (www.bioalliancepharma.com).

####

About BioAlliance Pharma SA
BioAlliance Pharma SA is a specialty pharmaceutical company focused on the treatment of opportunistic infections in cancer and HIV. The company develops and commercializes innovative products which address drug resistance issues. BioAlliance Pharma has launched its first portfolio product (Loramyc®) in France and, more recently, in the UK, Germany and Denmark, and has already received European Marketing Authorizations in Belgium and Luxemburg. The product has also completed a pivotal Phase III clinical trial in the United States in oropharyngeal candidiasis. The company is also performing a Phase III trial in labial herpes with acyclovir Lauriad® (which is based on the same Lauriad® muco-adhesive technology as Loramyc®, enabling targeted release at the disease site). BioAlliance Pharma also has a second technology (the Transdrug® nanoparticle technology, designed specifically for intracellular targeting) and, furthermore, is developing a new therapeutic entities program in oncology and infectious disease. BioAlliance Pharma has established several strategic alliances for commercializing Loramyc®, with agreements in 2007 for Europe (with the SpeBio joint venture) and the United States (with Par Pharmaceutical) and in 2008 for Asia (Korea, Malaysia, Singapore and Taiwan with Handok Pharmaceuticals and then China with Novamed). In May and August 2008, the company expanded its product portfolio by acquiring the Europe commercial rights to, respectively, ondansetron Oral Spray (OS) from NovaDel Pharma Inc. (Amex: NVD) and ondansetron RapidFilmTM from APR/Labtec.

Disclaimer

This communication expressly or implicitly contains certain forward-looking statements concerning BioAlliance Pharma SA and its business. Such statements involve certain known and unknown risks, uncertainties and other factors, which could cause the actual results, financial condition, performance or achievements of BioAlliance Pharma SA to be materially different from any future results, performance or achievements expressed or implied by such forward-looking statements. BioAlliance Pharma SA is providing this communication as of this date and does not undertake to update any forward-looking statements contained herein as a result of new information, future events or otherwise. For a discussion of risks and uncertainties which could cause actual results, financial condition, performance or achievements of BioAlliance Pharma SA to differ from those contained in the forward-looking statements, please refer to the Risk Factors ("Facteurs de Risque") section of the reference document approved by the AMF on April 11 2008 under the number R. 08-021, which is available on the AMF website (www.amf-france.org) or on BioAlliance Pharma S.A.'s website (www.bioalliancepharma.com).

For more information, please click here

Contacts:

BioAlliance Pharma SA
Dominique Costantini, President and CEO
Tel.: +33 1 45 58 76 01

or
Nicolas Fellmann, CFO
Tel.: +33 1 45 58 71 00

or
ALIZE RP
Caroline Carmagnol
Tel.: +33 6 64 18 99 59